The impact of stockpiling for Brexit on the pharmaceutical industry

The pharmaceutical industry has long anticipated that a no-deal Brexit could result in an international logistics crisis. As a result, pharmaceutical companies all over the world are preparing to stockpile in order to continue the flow of life-critical medications.

However, stockpiling is having a significant effect on available warehousing space in the UK, with three quarters of warehouse owners declaring they no longer have available space. In addition, pharmaceutical companies also lack the internal capacity to stockpile large quantities of medications and therefore face the worrying prospect of product shortages in the case of a no-deal Brexit.

For pharmaceutical companies who don’t have the option to stockpile due to a lack of warehousing space and face this potential shortage, our flexible infrastructure and priority delivery times enable us to provide smaller batches of patient information leaflets upon request. At least one member of our team is on hand 24/7 which means that we are able to step in and assist with any new requests as they come in.

Having two or more suppliers is one of the crucial ways pharmaceutical companies are able to circumvent supply chain disruption and we have regularly stepped into the role of secondary supplier for a number of pharmaceutical companies looking to guarantee the continuous flow of pharmaceutical products in busier or unprecedented times.

Further to this, fluctuations in demand for certain pharmaceutical products can be more manageable if you have a choice of suppliers with whom to adjust order volumes.

If you’re interested in hearing more about our end-to-end printing and folding service of patient information leaflets, get in touch with a member of our team today.

To stay up-to-date with the latest news from Technoprint, follow us on Facebook, LinkedIn and Twitter.